» Articles » PMID: 18302268

Differential Expression of MUC1 and Carbohydrate Antigens in Primary and Secondary Head and Neck Squamous Cell Carcinoma

Overview
Journal Head Neck
Date 2008 Feb 28
PMID 18302268
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In head and neck squamous cell carcinoma (HNSCC), tumor markers may be helpful to evaluate prognosis accurately as well as to improve therapy selection. Detection of human MUC1 has been widely employed for the evaluation of carcinoma patients. This article aims to study MUC1, Tn, sTn, and Lewis antigenic expression in primary HNSCC, lymph node metastasis, and local recurrences.

Methods: We used immunohistochemistry, tissue homogenization and differential centrifugation, isopycnic density gradient centrifugation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western blot.

Results: In primary tumors, MUC1 was detected in 80.0% of the samples; sLewis x in 23.2%, Lewis x in 45.6%, and Lewis y in 40.8%. Tn and sTn were found in 4.0% and 6.4% of samples, respectively. In metastatic lymph nodes, MUC1 showed a similar positive reaction as in primary tumors. Lewis y was detected in 20% lymph nodes whereas Lewis x, sLewis x, Tn, and sTn did not show differences. Some recurrences expressed MUC1 and only a few Lewis antigens, whereas Tn and sTn were not detected.

Conclusion: In primary HNSCC and metastatic nodes, a high expression of MUC1 and Lewis antigens was detected that diminished in local recurrences. We also found that differentiated tumors mainly expressed a linear pattern of MUC1CT and Lewis x.

Citing Articles

Recurrent Oropharyngeal Squamous Cell Carcinomas Maintain Anti-tumor Immunity and Multinucleation Levels Following Completion of Radiation.

Castro P, Corredor G, Koyuncu C, Nordstrom L, Tiji M, Leavitt T Head Neck Pathol. 2023; 17(4):952-960.

PMID: 37995073 PMC: 10739687. DOI: 10.1007/s12105-023-01597-z.


Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer.

Ji Z, Fang Z, Dong X, Wang J, Wan X, Yan A Eur Arch Otorhinolaryngol. 2022; 279(11):5277-5288.

PMID: 35829804 DOI: 10.1007/s00405-022-07433-4.


Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer.

Pack C, Bommireddy R, Munoz L, Patel J, Bozeman E, Dey P Hum Vaccin Immunother. 2020; 16(12):3184-3193.

PMID: 32530786 PMC: 8641616. DOI: 10.1080/21645515.2020.1754691.


The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.

Weed D, Zilio S, Reis I, Sargi Z, Abouyared M, Gomez-Fernandez C Front Immunol. 2019; 10:1206.

PMID: 31214178 PMC: 6554471. DOI: 10.3389/fimmu.2019.01206.


Prognostic and clinicopathological significance of MUC expression in head and neck cancer: a systematic review and meta-analysis.

Lu H, Liang D, Zhu Y, Xu W, Zhou K, Liu L Oncotarget. 2017; 8(56):96359-96372.

PMID: 29221212 PMC: 5707106. DOI: 10.18632/oncotarget.19648.